CD

Cancer Discovery

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.

Looking to publish in Cancer Discovery? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 33.3
Quartile Q1
Open Access Type Closed
ISSN 2159-8274
eISSN 2159-8290
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors without financial support may apply for a waiver of the fixed publication fee at submission.

Submission Instructions

Cancer Discovery accepts the following article types. Click on an article type to view submission instructions.

Original Research Articles

Cover Letter Cover letter is strongly encouraged. Cover letter must describe how any associated manuscript is related to the submission and must detail any use of AI to produce new text, images, or other material for the manuscript.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the order of title page, text and references, tables, figure legends, and figures, and it must include a Data Availability subsection at the end of the Materials and Methods section. Manuscript must include a conflict of interest disclosure on the title page, funding information and acknowledgments, a declaration of any AI use in the acknowledgments and appropriate manuscript section, and a Code Availability Statement if custom computer code was used.
References References must be numbered in order of first mention and cited in the text by number only. For references with more than 6 authors, list the first 6 followed by et al., and for references with 6 or fewer authors, list all authors.
Figures & Tables For initial submission, figures should appear in sequential order adjacent to their legends, ideally where first cited, and supplementary files must be uploaded separately rather than appended to the main manuscript. Each figure must have a legend, figures and tables must be cited in sequential order, and the title page must state the total number of figures and tables.
Reformat to Cancer Discovery using Livewrite Premium

Review Manuscript

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission and detail any use of AI to produce new text, images, or other material for the manuscript.
Abstract Abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. Manuscript must include funding information, an Acknowledgments section naming nonauthor contributors and any generative AI technologies involved, a title page with word count and total number of figures and tables, a detailed conflict of interest disclosure statement, and declarations of any AI use in the manuscript and acknowledgments.
References References must be numbered in the order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by et al. when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should appear in sequential order adjacent to their legends and ideally where first cited in the text, while supplementary files must be uploaded separately and not appended to the main manuscript file. Each figure must include a legend with a short title sentence and description, multi-panel figures must have labeled panels described in the legend, figures and tables must be cited sequentially in the text, and every table must have a descriptive title and enough explanatory information to stand alone.
Reformat to Cancer Discovery using Livewrite Premium

Meta-Analysis

Cover Letter Cover letter is strongly encouraged but not required. Cover letter must describe how any associated manuscript is related to the current submission and must describe in detail any use of AI to produce new text, images, or other material.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript must include funding information, acknowledgments for nonauthor contributors and any generative AI technologies used, a detailed conflict of interest disclosure on the title page, and an appropriate manuscript section declaring AI use.
References References must be numbered in order of first mention in the text and cited by number only, listing all authors when there are 6 or fewer and the first 6 followed by et al. when there are more than 6.
Figures & Tables For initial submission, figures should be presented in sequential order adjacent to their legends, ideally where first cited in the text, while supplementary files must be uploaded separately and not appended to the main manuscript. Each table must be cited in sequential order and have a descriptive title, and each figure must be cited and numbered in order and accompanied by a legend with a short title sentence and panel descriptions if applicable.
Reformat to Cancer Discovery using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript must include funding information, acknowledgments for nonauthor contributors and any generative artificial intelligence technologies used, a detailed conflict of interest statement on the title page, and an AI declaration in the acknowledgments and appropriate manuscript section when applicable.
References References must be numbered in the order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by et al. when there are more than 6 authors.
Figures & Tables For initial submission, figures should be placed in sequential order adjacent to their legends, ideally where first cited in the text, while supplementary files must be uploaded separately and not appended to the main manuscript. Each figure must have a legend, figures and tables must be cited in sequential order, and the title page must report the total number of figures and tables.
Reformat to Cancer Discovery using Livewrite Premium

Recent Publications

BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCER

Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, Yuan Yang, Shraddha Rastogi, Nahoko Sato, Sunmin Lee, Yo-Ting Tsai, Sophie Zhuang, Amira Kazi, Yue Huang, Parth Desai, Samantha Nichols, Linda Sciuto, Danielle Pinkiert, George Chrisafis, Max Greenberg, D. Nathan. Biery, Rusul Al-Marayaty, Howard H. Yang, Maxwell P. Lee, Christopher W. Schultz, Rajaa El Meskini, Devon Atkinson, Kristen Fousek, James L. Gulley, Jeffrey Schlom, Masashi Sato, Roshan L. Shrestha, Ajit Kumar. Sharma, Mohit Kumar Jolly, Claudia Palena, Lalage M. Wakefield, Anish Thomas

10.1158/2159-8290.cd-25-1454
View Publication

Wildfire Smoke Exposure Associated with Increased Cancer Risk

-

10.1158/2159-8290.cd-nw2026-0042
View Publication

scSurvival: Single-Cell Survival Analysis of Clinical Cancer Cohort Data at Cellular Resolution

Tao Ren, Faming Zhao, Canping Chen, Le Zhou, Ling-Yun Wu, Gordon B. Mills, Lisa M. Coussens, Zheng Xia

10.1158/2159-8290.cd-25-0965
View Publication

SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities

Benedikt Pelzer, Cem Meydan, Isaac M. Spiegel, Ioannis Karagiannidis, Min Xia, Matt Teater, Emma M. Welter, Zowie E. Searcy, Laura K. Hilton, Darko Barisic, Amos Fong, Pengyan Fa, Shenon Sethi, Irem S. Isgor, Jessie J. Fielding, Alireza Karbalayghareh, Colin S. Burdette, Sravya Tumuluru, Sonia M. Debek, Sunjae Lee, Ramon Massoni-Badosa, Ceyda Durmaz, Eralda Salataj, Prasath Pararajalingam, Zhengming Chen, Richard J. Pelzl, Sanket Shah, Martin A. Rivas, Kenneth B. Hoehn, Coraline Mlynarczyk, Hannah M. Isles, Xiang Wang, Ahmet Dogan, Kojo S.J. Elenitoba-Johnson, David W. Scott, Kostiantyn Dreval, Ryan D. Morin, Christina S. Leslie, Rishi Puri, Jacob B. Geri, Christopher R. Chin, Amy Chadburn, Christopher E. Mason, Hans Christian. Reinhardt, Montserrat C. Anguera, Wendy Béguelin, Leandro Venturutti, Ari M. Melnick

10.1158/2159-8290.cd-25-1458
View Publication

Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study

Salah-Eddine Bentebibel, Daniel J. McGrail, Veena Kochat, Emre Arslan, Reham Abdel-Wahab, Barbara Pazdrak, Ravi Murthy, Nourel Hoda M. Tahon, Sung-Nam Cho, Dzifa Y. Duose, Khalida Wani, Jingjing Liu, Cara Haymaker, Javier A. Gomez, Heather Sonnemann, Arjun S. Katailiha, Barbara Nassif-Rausseo, Maha Rahim, Irene Li, Aaron T. Mayer, Xiaodong Yang, Frank J. Hsu, Jianhua Zhang, Daniel H. Johnson, Rodabe N. Amaria, Isabella C. Glitza Oliva, Sapna P. Patel, Patrick Hwu, Khaled M. Elsayes, Hussein A. Tawbi, Jared K. Burks, Chantale Bernatchez, Michael A. Davies, Kunal Rai, Gregory Lizee, Suhendan Ekmekcioglu, Adi Diab

10.1158/2159-8290.cd-25-1551
View Publication

Frequently asked questions

How long does it take to publish?

Decisions are typically returned within 35 days of submission. Accepted author manuscripts are usually posted OnlineFirst within 48 hours following formal acceptance.

Reformat to Cancer Discovery using Livewrite Premium

Is a cover letter required?

A cover letter is strongly encouraged for initial submission.

Reformat to Cancer Discovery using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item; authors without financial support may apply for a waiver of the fixed publication fee at submission.

Reformat to Cancer Discovery using Livewrite Premium

Research Topics

Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Lung Cancer Treatments and Mutations Epigenetics and DNA Methylation Immunotherapy and Immune Responses Immune Cell Function and Interaction RNA modifications and cancer Protein Degradation and Inhibitors Cancer, Hypoxia, and Metabolism Immune cells in cancer Melanoma and MAPK Pathways Acute Myeloid Leukemia Research PI3K/AKT/mTOR signaling in cancer Cancer Cells and Metastasis Pancreatic and Hepatic Oncology Research Colorectal Cancer Treatments and Studies Chronic Lymphocytic Leukemia Research Cancer-related Molecular Pathways HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Cancer-related gene regulation Peptidase Inhibition and Analysis DNA Repair Mechanisms Ubiquitin and proteasome pathways

Related Journals

IJ
International Journal Of Gynecological Cancer BMJ
CT
Cancer Treatment Reviews Elsevier BV
OO
Oral Oncology Elsevier BV
CN
Cancer Nursing LIPPINCOTT WILLIAMS & WILKINS
TL
Translational Lung Cancer Research AME PUBLISHING COMPANY
IJ
International Journal Of Oncology Spandidos Publishing